CEO Paul Chaney details the company’s plans to move forward with $11 million in new capital. He also recounts how his unplanned entry into ophthalmology led him to appreciate how special the specialty truly is. Chaney ...
Welcome to Our OIS Podcast Channel
Ophthalmology’s leaders convene at the Ophthalmology Innovation Summits held several times a year. OIS Podcasts keeps the conversation going the entire year. In weekly podcasts, Host Tom Salemi interviews the most influential industry executives, investors, KOLs, and researchers about what they see as the most exciting approaches to finding new ways to treat eye disease. Join the conversation by subscribing to the OIS Podcast.
ExSight Capital, Partner Firas Rahhal, MD, Are Building a Successful Record as Impact Investor
With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and partner Firas M. ...
Dr. Pravin Dugel Picks Possible Winners in Race to Deliver New Retinal Treatments
Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies ...
Hatteras’ Shaffer Found a Model That Works at Inspire; Now She Uses It When Making Investments
Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or into the partnership at Hatteras Venture Partners. But the ...
Digital Health Is Dead? Don’t Tell Mark Blumenkranz, the FDA, or the Organizers of an Oct. Workshop
Accomplished ophthalmologist Mark S. Blumenkranz, MD, moved early into the Digital Health space by co-founding Digisight, one of the more advanced efforts in ophthalmology. Six years, later, Dr. Blumenkranz still sees ...
What Was the Most Difficult Part of Successfully Transitioning to CMO? We Ask B&L’s Cal Roberts
In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade a thriving ophthalmology practice to serve as chief medical officer at the ...
Imperial College’s Dr. Cordeiro Explains How DARC May Bring Early Light to Disease, Shorten Trials
Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, shares details of the institute’s detection of apoptosing retinal cells (DARC) scan – which employs a new retinal ...
Why Did Charles Semba, MD, Switch Specialties and How Did He Find a Home in Ophthalmology?
Charles Semba, MD, is becoming known as a force in the development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery ...
OIS@ASRS Co-Chairs Give High Marks and Hopes for Innovators Looking at the Back of the Eye
OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the second OIS@ASRS. Dr. Humayun, the outgoing ASRS president, shares details on ...
Should You Be at OIS@ASRS on Thursday? Take an Insider Look at the Agenda with Emmett Cunningham
OIS Co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, managing director, Clarus Funds, walks us through the agenda of Thursday’s OIS@ASRS. What areas of retina will dominate the headlines for the next 12 months? Learn ...
What Does TearScience Deal Mean for J&J? Group Chair Ashley McEvoy Shines Light on Future Plans
Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group ...
Allegro’s Poised to Deliver Positive News at ASRS; Could an IPO Be Next? We Ask Vicken Karageozian
Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular ...
- 1
- 2
- 3
- …
- 14
- Next Page »
